In a report published Wednesday, Jefferies & Company reiterated its Buy rating on Pfizer (NYSE: PFE), and raised its price target from $27.00 to $31.00. Jefferies & Company noted, “We see Pharmaceuticals as remaining attractive in 2013, but unlikely to return the same level of relative performance as in 2012.